MET exon 14 skipping and amplifications both are over-represented among non-smokers, yet smokers are more common than in patients with EGFR or ALK-driven NSCLC, with 61–74% and 77% of patients being smokers among patients with exon 14 skipping and amplification, respectively [212]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.